RIEFLIN WILLIAM JL — SEC insider filings

SEC reporting owner CIK 1182471. 20 insider filings on record with FilingPulse; latest filed 2026-10-26.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2020-11-20 to 2026-10-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
RAPT Therapeutics, Inc. (RAPT)Director81 leg · 10,000 sh · $162,200—7
NGM BIOPHARMACEUTICALS INC (NGM)Director4——11
Lyell Immunopharma, Inc. (LYEL)Director6——6
Lycia Therapeutics, Inc. (LYCA)Director2——2

Insider filings — RIEFLIN WILLIAM JL

FiledFormIssuerReported transactionsSource
2026-10-264Lycia Therapeutics, Inc. (LYCA)Grant/award (A): 24,840 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2026-10-223Lycia Therapeutics, Inc. (LYCA)Holdings only — no transactions reportedEDGAR
2026-06-124Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 9,250 (derivative) @ $0EDGAR
2025-05-194Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 130,000 (derivative) @ $0EDGAR
2024-06-174Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 130,000 (derivative) @ $0EDGAR
2024-05-234RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 36,490 (derivative) @ $0EDGAR
2024-04-084NGM BIOPHARMACEUTICALS INC (NGM)Code (U): 5,172 · Code (U): 2,769,168 · Disposition to issuer (D): 78,407 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 75,000 (derivative) · +2 moreEDGAR
2024-04-014RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 11,871 (derivative) @ $7.58EDGAR
2023-09-084Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 55,000 (derivative) @ $0EDGAR
2023-06-204Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 65,000 (derivative) @ $0EDGAR
2023-05-254RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 12,940 (derivative) @ $0EDGAR
2023-05-124NGM BIOPHARMACEUTICALS INC (NGM)Grant/award (A): 78,407 (derivative) @ $0EDGAR
2023-04-104RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 6,026 (derivative) @ $14.52EDGAR
2022-06-104Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 65,000 (derivative) @ $0EDGAR
2022-05-264RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 8,500 (derivative) @ $0EDGAR
2022-04-044RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 5,207 (derivative) @ $16.80EDGAR
2022-03-044NGM BIOPHARMACEUTICALS INC (NGM)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2021-06-244RAPT Therapeutics, Inc. (RAPT)Grant/award (A): 7,500 (derivative) @ $0EDGAR
2021-03-184NGM BIOPHARMACEUTICALS INC (NGM)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2020-11-204RAPT Therapeutics, Inc. (RAPT)Purchase (P): 10,000 @ $16.22EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1182471 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs